These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy. Farlow MR; Grossberg GT; Meng X; Olin J; Somogyi M Int J Geriatr Psychiatry; 2011 Dec; 26(12):1236-43. PubMed ID: 22068922 [TBL] [Abstract][Full Text] [Related]
13. Domain-specific cognitive effects of tramiprosate in patients with mild to moderate Alzheimer's disease: ADAS-cog subscale results from the Alphase Study. Saumier D; Duong A; Haine D; Garceau D; Sampalis J J Nutr Health Aging; 2009 Nov; 13(9):808-12. PubMed ID: 19812871 [TBL] [Abstract][Full Text] [Related]
14. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial. Farlow M; Potkin S; Koumaras B; Veach J; Mirski D Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489 [TBL] [Abstract][Full Text] [Related]
15. A clinical study of lupron depot in the treatment of women with Alzheimer's disease: preservation of cognitive function in patients taking an acetylcholinesterase inhibitor and treated with high dose lupron over 48 weeks. Bowen RL; Perry G; Xiong C; Smith MA; Atwood CS J Alzheimers Dis; 2015; 44(2):549-60. PubMed ID: 25310993 [TBL] [Abstract][Full Text] [Related]
16. A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Aisen PS; Saumier D; Briand R; Laurin J; Gervais F; Tremblay P; Garceau D Neurology; 2006 Nov; 67(10):1757-63. PubMed ID: 17082468 [TBL] [Abstract][Full Text] [Related]
17. Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial. Sparks DL; Connor DJ; Sabbagh MN; Petersen RB; Lopez J; Browne P Acta Neurol Scand Suppl; 2006; 185():3-7. PubMed ID: 16866904 [TBL] [Abstract][Full Text] [Related]
18. Effects of AZD3480 on cognition in patients with mild-to-moderate Alzheimer's disease: a phase IIb dose-finding study. Frölich L; Ashwood T; Nilsson J; Eckerwall G; J Alzheimers Dis; 2011; 24(2):363-74. PubMed ID: 21258153 [TBL] [Abstract][Full Text] [Related]
19. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lannfelt L; Blennow K; Zetterberg H; Batsman S; Ames D; Harrison J; Masters CL; Targum S; Bush AI; Murdoch R; Wilson J; Ritchie CW; Lancet Neurol; 2008 Sep; 7(9):779-86. PubMed ID: 18672400 [TBL] [Abstract][Full Text] [Related]
20. Detecting treatment effects with combinations of the ADAS-cog items in patients with mild and moderate Alzheimer's disease. Ihl R; Ferris S; Robert P; Winblad B; Gauthier S; Tennigkeit F Int J Geriatr Psychiatry; 2012 Jan; 27(1):15-21. PubMed ID: 21384431 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]